VLTR 557
Alternative Names: VLTR-557Latest Information Update: 26 Apr 2023
At a glance
- Originator Valitor
- Class Drug conjugates; Eye disorder therapies; Immunoconjugates; Single-domain antibodies
- Mechanism of Action Vascular endothelial growth factors inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Diabetic macular oedema; Diabetic retinopathy; Retinal vascular occlusion; Wet age-related macular degeneration
Most Recent Events
- 24 Apr 2023 Pharmacokinetics, pharmacodynamics and adverse events data from a preclinical trial in wet age-related macular degeneration released by Valitor
- 10 Oct 2022 Preclinical trials in Diabetic macular oedema in USA (unspecified route) Before October 2022 (Valitor pipeline, October 2022)
- 10 Oct 2022 Preclinical trials in Diabetic retinopathy in USA (unspecified route) Before October 2022 (Valitor pipeline, October 2022)